Nasdaq Hearings Panel Granted Alzamend's Request To Continue Its Listing, Subject To Alzamend Demonstrating Compliance, On Or Before September 23, 2024
Nasdaq Hearings Panel Granted Alzamend's Request To Continue Its Listing, Subject To Alzamend Demonstrating Compliance, On Or Before September 23, 2024
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), announced today that the Nasdaq Hearings Panel ("Panel") granted Alzamend's request to continue its listing on The Nasdaq Capital Market ("Nasdaq"), subject to Alzamend demonstrating compliance, on or before September 23, 2024, with Listing Rule 5550(b)(1), which requires stockholder equity of at least $2.5 million (the "Stockholder Equity Rule"), and satisfying all applicable requirements for continued listing on Nasdaq.
Alzamend Neuro, Inc.（納斯達克股票代碼：ALZN）（“Alzamend”）是一家臨床階段的生物製藥公司，專注於開發用於治療阿爾茨海默氏病（“阿爾茨海默氏症”）、躁鬱症（“BD”）、重性抑鬱症（“MDD”）和創傷後應激障礙（“創傷後應激障礙”）的新產品，今天宣佈，納斯達克聽證小組（“小組”）（“小組”）”）批准了Alzamend繼續在納斯達克資本市場（“納斯達克”）上市的請求，前提是Alzamend在2024年9月23日當天或之前證明遵守了《上市規則》5550 (b) (1)，該規則要求股東權益至少爲250萬美元（“股東權益規則”），並滿足繼續在納斯達克上市的所有適用要求。
譯文內容由第三人軟體翻譯。